Solventum (NYSE:SOLV) Cut to Hold at Wall Street Zen

Solventum (NYSE:SOLV) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other equities research analysts also recently issued reports on the stock. Mizuho set a $100.00 price target on shares of Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. BTIG Research restated a “buy” rating and set a $100.00 target price on shares of Solventum in a research note on Friday, February 27th. Wells Fargo & Company dropped their target price on Solventum from $86.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and an average target price of $93.70.

Solventum Stock Performance

Solventum stock opened at $69.30 on Friday. The firm has a market capitalization of $12.02 billion, a PE ratio of 7.81, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. Solventum has a one year low of $60.70 and a one year high of $88.20. The stock’s 50 day moving average price is $77.62 and its 200 day moving average price is $76.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter last year, the company earned $1.41 earnings per share. Solventum’s revenue for the quarter was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, sell-side analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

Solventum announced that its board has authorized a stock buyback program on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Solventum

Several large investors have recently modified their holdings of SOLV. Vanguard Group Inc. increased its holdings in Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after buying an additional 867,837 shares during the last quarter. Independent Franchise Partners LLP grew its position in shares of Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after acquiring an additional 2,456,451 shares in the last quarter. State Street Corp increased its holdings in shares of Solventum by 2.0% in the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock valued at $502,759,000 after acquiring an additional 124,490 shares during the last quarter. Davis Selected Advisers raised its position in shares of Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after acquiring an additional 702,461 shares in the last quarter. Finally, Boston Partners lifted its stake in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.